[go: up one dir, main page]

NI202000036A - Anticuerpo específicos para el transcrito semillar a la inmunoglobulina tipo 3 (ilt3) y sus usos. - Google Patents

Anticuerpo específicos para el transcrito semillar a la inmunoglobulina tipo 3 (ilt3) y sus usos.

Info

Publication number
NI202000036A
NI202000036A NI202000036A NI202000036A NI202000036A NI 202000036 A NI202000036 A NI 202000036A NI 202000036 A NI202000036 A NI 202000036A NI 202000036 A NI202000036 A NI 202000036A NI 202000036 A NI202000036 A NI 202000036A
Authority
NI
Nicaragua
Prior art keywords
ilt3
transcript
seed
specific antibody
immunoglobulin type
Prior art date
Application number
NI202000036A
Other languages
English (en)
Inventor
A Meehl Michael
E Brandish Philip
Fayadat-Dilman Laurence
JUAN Veronica
Mieczkowski Carl
Singh Latika
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of NI202000036A publication Critical patent/NI202000036A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen anticuerpos monoclonales no promiscuos humanizados específicos para el transcrito similar a la inmunoglobulina tipo 3 (ILT3), también conocido como receptor de tipo inmunoglobulina de leucocitos de la subfamilia B miembro 4 (LILRB4).
NI202000036A 2017-11-17 2020-05-08 Anticuerpo específicos para el transcrito semillar a la inmunoglobulina tipo 3 (ilt3) y sus usos. NI202000036A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762587604P 2017-11-17 2017-11-17

Publications (1)

Publication Number Publication Date
NI202000036A true NI202000036A (es) 2020-09-24

Family

ID=64572590

Family Applications (1)

Application Number Title Priority Date Filing Date
NI202000036A NI202000036A (es) 2017-11-17 2020-05-08 Anticuerpo específicos para el transcrito semillar a la inmunoglobulina tipo 3 (ilt3) y sus usos.

Country Status (26)

Country Link
US (6) US11111297B2 (es)
EP (1) EP3710479A2 (es)
JP (1) JP7194481B2 (es)
KR (1) KR102478433B1 (es)
CN (2) CN120058946A (es)
AR (1) AR113696A1 (es)
AU (1) AU2018367524B2 (es)
BR (1) BR112020009759A8 (es)
CA (1) CA3082409A1 (es)
CL (1) CL2020001240A1 (es)
CO (1) CO2020006405A2 (es)
CR (1) CR20200204A (es)
DO (1) DOP2020000074A (es)
EA (1) EA202091228A1 (es)
EC (1) ECSP20032082A (es)
GE (2) GEAP202315366A (es)
IL (1) IL274574A (es)
JO (1) JOP20200131A1 (es)
MA (1) MA50900A (es)
MX (2) MX2020005128A (es)
NI (1) NI202000036A (es)
PE (1) PE20210475A1 (es)
PH (1) PH12020550890A1 (es)
SG (1) SG11202004426SA (es)
TW (1) TWI816715B (es)
WO (1) WO2019099597A2 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2691357C (en) 2007-06-18 2014-09-23 N.V. Organon Antibodies to human programmed death receptor pd-1
MA50900A (fr) * 2017-11-17 2020-09-23 Merck Sharp & Dohme Anticorps spécifiques du transcrit 3 de type immunoglobuline (ilt3) et leurs utilisations
PH12022551462A1 (en) * 2019-12-19 2023-11-13 Ngm Biopharmaceuticals Inc Ilt3-binding agents and methods of use thereof
PE20221894A1 (es) 2020-05-01 2022-12-13 Ngm Biopharmaceuticals Inc Agentes de union a ilt y metodos para su uso
MX2023010825A (es) * 2021-03-19 2023-12-08 Merck Sharp & Dohme Llc Metodos para tratar el cancer con anticuerpos anti-ilt3.
CA3227172A1 (en) * 2021-07-28 2023-02-02 Cai WU Methods for treating acute myeloid leukemia with anti-ilt3 antibodies
CN116082502A (zh) * 2021-11-08 2023-05-09 复旦大学 Galectin8与LILRB4结合的调节剂及其应用
WO2023140875A1 (en) * 2022-01-19 2023-07-27 Ngm Biopharmaceuticals, Inc. Uses of ilt3-binding agents
CA3245704A1 (en) 2022-03-29 2023-10-05 Ngm Biopharmaceuticals, Inc. ILT3 AND CD3 LINKING AGENTS AND THEIR METHODS OF USE
KR20250025354A (ko) 2022-04-25 2025-02-21 비온드 바이오로직스 엘티디 항-ilt3 항체 및 이의 용도
WO2023235699A1 (en) 2022-05-31 2023-12-07 Jounce Therapeutics, Inc. Antibodies to lilrb4 and uses thereof
CN115925942A (zh) * 2022-06-08 2023-04-07 北京科诺信诚科技有限公司 靶向人lilrb4的纳米抗体及其应用
WO2024235317A1 (zh) 2023-05-18 2024-11-21 南京维立志博生物科技有限公司 结合lilrb4和cd3的抗体及其用途
WO2025062392A1 (en) 2023-09-20 2025-03-27 Biond Biologics Ltd. Anti-ilt3 blockade combinations
WO2025141589A1 (en) 2023-12-31 2025-07-03 Biond Biologics Ltd. Treatment of cancer with anti-ilt3 antibodies

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3162749D1 (en) 1980-06-30 1984-04-26 Ibm Data transfer apparatus
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
WO1993011161A1 (en) 1991-11-25 1993-06-10 Enzon, Inc. Multivalent antigen-binding proteins
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
GB9818110D0 (en) 1998-08-19 1998-10-14 Weston Medical Ltd Needleless injectors and other devices
US6096002A (en) 1998-11-18 2000-08-01 Bioject, Inc. NGAS powered self-resetting needle-less hypodermic jet injection apparatus and method
JP2002531466A (ja) 1998-12-01 2002-09-24 プロテイン デザイン ラブス， インコーポレイテッド γ−インターフェロンに対するヒト化抗体
WO2003000199A2 (en) * 2001-06-25 2003-01-03 The Trustees Of Columbia University In The City Of New York Ilt3 and ilt4-related compositions and methods
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
CA2391438A1 (en) 2002-05-01 2003-11-01 Procyon Biopharma Inc. Psp94 diagnostic reagents and assays
JP4511943B2 (ja) 2002-12-23 2010-07-28 ワイス エルエルシー Ｐｄ−１に対する抗体およびその使用
EP1799840A4 (en) * 2004-09-03 2009-02-18 Univ Columbia ILT3-POLYPEPTIDES AND USES THEREOF
PL2161336T5 (pl) 2005-05-09 2017-10-31 Ono Pharmaceutical Co Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi
AU2006261127B2 (en) * 2005-06-17 2012-03-15 Merck Sharp & Dohme Corp. ILT3 binding molecules and uses therefor
CN104356236B (zh) 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
RS53752B1 (sr) * 2005-12-20 2015-06-30 Sbi Biotech Co. Ltd. Antitelo protiv ilt7
US20090202544A1 (en) 2006-02-02 2009-08-13 The Trustees Of Columbia University In The City Of New York Methods of Treating Diseases by Targeting Silt3
US7777008B2 (en) * 2006-06-19 2010-08-17 Tolerx, Inc. ILT3 binding molecules and uses therefor
GB0705775D0 (en) 2007-03-26 2007-05-02 Affitech As Product
CA2691357C (en) 2007-06-18 2014-09-23 N.V. Organon Antibodies to human programmed death receptor pd-1
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
CN101855242B (zh) 2007-09-14 2014-07-30 阿迪马布有限责任公司 合理设计的合成抗体文库及其用途
HUE034465T2 (en) 2008-02-11 2018-02-28 Cure Tech Ltd Monoclonal antibodies for tumor treatment
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
EP2328919A2 (en) 2008-08-25 2011-06-08 Amplimmune, Inc. Pd-i antagonists and methods for treating infectious disease
PL2350129T3 (pl) 2008-08-25 2015-12-31 Amplimmune Inc Kompozycje antagonistów PD-1 i sposoby stosowania
EP4331604B9 (en) 2008-12-09 2025-07-23 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
ES2629337T3 (es) 2009-02-09 2017-08-08 Inserm - Institut National De La Santé Et De La Recherche Médicale Anticuerpos contra PD-1 y anticuerpos contra PD-L1 y usos de los mismos
CN101830978A (zh) * 2009-03-09 2010-09-15 中国科学院微生物研究所 一种人免疫球蛋白样受体突变体及其应用
US20130017199A1 (en) 2009-11-24 2013-01-17 AMPLIMMUNE ,Inc. a corporation Simultaneous inhibition of pd-l1/pd-l2
WO2011120135A1 (en) 2010-03-29 2011-10-06 Zymeworks, Inc. Antibodies with enhanced or suppressed effector function
WO2011127543A1 (en) 2010-04-16 2011-10-20 Transbio Ltd Proteins that bind pi16 and uses thereof
KR101614195B1 (ko) 2011-03-29 2016-04-20 로슈 글리카트 아게 항체 Fc 변이체
US9696312B2 (en) 2011-09-02 2017-07-04 The Trustees Of Columbia University In The City Of New York Diagnosis and treatment of cancer expressing ILT3 or ILT3 ligand
AU2013201121A1 (en) * 2011-09-20 2013-04-04 Vical Incorporated Synergistic anti-tumor efficacy using alloantigen combination immunotherapy
US20150174203A1 (en) 2012-05-30 2015-06-25 Icahn School Of Medicine At Mount Sinai Compositions And Methods For Modulating Pro-Inflammatory Immune Response
EP2948475A2 (en) 2013-01-23 2015-12-02 AbbVie Inc. Methods and compositions for modulating an immune response
PL3594240T3 (pl) 2013-05-20 2024-04-02 F. Hoffmann-La Roche Ag Przeciwciała przeciwko receptorowi transferyny i sposoby ich zastosowania
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
IL294043B2 (en) 2014-09-28 2024-10-01 Univ California Modulation of stimulatory and non-stimulatory myeloid cells
WO2016127427A1 (zh) 2015-02-15 2016-08-18 华为技术有限公司 电子设备外壳的加工方法、电子设备外壳及电子设备
CA2977544C (en) * 2015-03-06 2023-12-19 The Board Of Regents Of The University Of Texas System Anti-lilrb antibodies and their use in detecting and treating cancer
WO2017015227A1 (en) 2015-07-17 2017-01-26 The Trustees Of Columbia University In The City Of New York Methods of treating cd166-expressing cancer
UA121914C2 (uk) * 2015-11-18 2020-08-10 Мерк Шарп І Доум Корп. Молекула, що зв'язує pd1 і lag3
WO2018044238A1 (en) 2016-08-31 2018-03-08 Agency For Science, Technology And Research Methods for the identification, targeting and isolation of human dendritic cell (dc) precursors "pre-dc" and their uses thereof
EP3538141A4 (en) 2016-11-10 2020-07-15 Merck Sharp & Dohme Corp. LIGAND ILT3
CA3053164A1 (en) 2017-02-09 2018-08-16 Bluefin Biomedicine, Inc. Anti-ilt3 antibodies and antibody drug conjugates
MA50900A (fr) * 2017-11-17 2020-09-23 Merck Sharp & Dohme Anticorps spécifiques du transcrit 3 de type immunoglobuline (ilt3) et leurs utilisations
MX2023010825A (es) * 2021-03-19 2023-12-08 Merck Sharp & Dohme Llc Metodos para tratar el cancer con anticuerpos anti-ilt3.
CA3227172A1 (en) * 2021-07-28 2023-02-02 Cai WU Methods for treating acute myeloid leukemia with anti-ilt3 antibodies
WO2023017525A1 (en) * 2021-08-11 2023-02-16 OncoHost Ltd. Predicting patient response
WO2023159152A2 (en) * 2022-02-17 2023-08-24 Immune-Onc Therapeutics, Inc. Combination therapy of lilrb antagonist and pd-1/pd-l1 axis inhibitor
WO2023235699A1 (en) * 2022-05-31 2023-12-07 Jounce Therapeutics, Inc. Antibodies to lilrb4 and uses thereof
WO2024026019A1 (en) * 2022-07-28 2024-02-01 Merck Sharp & Dohme Llc Methods for treating chronic myelomonocytic leukemia with anti-ilt3 antibodies

Also Published As

Publication number Publication date
IL274574A (en) 2020-06-30
JP7194481B2 (ja) 2022-12-22
CN111712518B (zh) 2025-03-25
AU2018367524A1 (en) 2020-06-11
EA202091228A1 (ru) 2020-08-12
WO2019099597A2 (en) 2019-05-23
WO2019099597A3 (en) 2019-06-13
US12441792B2 (en) 2025-10-14
US20190153093A1 (en) 2019-05-23
DOP2020000074A (es) 2020-08-31
US20220033497A1 (en) 2022-02-03
TWI816715B (zh) 2023-10-01
BR112020009759A2 (pt) 2020-11-03
GEP20237565B (en) 2023-11-10
ECSP20032082A (es) 2020-08-31
MA50900A (fr) 2020-09-23
CL2020001240A1 (es) 2020-12-18
CA3082409A1 (en) 2019-05-23
JP2021503280A (ja) 2021-02-12
PH12020550890A1 (en) 2021-04-12
US11111297B2 (en) 2021-09-07
CO2020006405A2 (es) 2020-06-09
AU2018367524B2 (en) 2022-09-15
KR102478433B1 (ko) 2022-12-15
CR20200204A (es) 2020-06-18
US12435133B2 (en) 2025-10-07
US20220010011A1 (en) 2022-01-13
PE20210475A1 (es) 2021-03-08
GEAP202315366A (en) 2023-07-25
KR20200083598A (ko) 2020-07-08
EP3710479A2 (en) 2020-09-23
JOP20200131A1 (ar) 2020-05-28
SG11202004426SA (en) 2020-06-29
TW201922786A (zh) 2019-06-16
CN111712518A (zh) 2020-09-25
US20220025043A1 (en) 2022-01-27
US20220025042A1 (en) 2022-01-27
AR113696A1 (es) 2020-06-03
MX2020005128A (es) 2020-07-27
CN120058946A (zh) 2025-05-30
US20220010010A1 (en) 2022-01-13
BR112020009759A8 (pt) 2023-01-31
MX2025000940A (es) 2025-03-07

Similar Documents

Publication Publication Date Title
NI202000036A (es) Anticuerpo específicos para el transcrito semillar a la inmunoglobulina tipo 3 (ilt3) y sus usos.
BR112022010206A2 (pt) Receptores de antígeno quiméricos e usos dos mesmos
CL2020000938A1 (es) Anticuerpos anti-tigit, sus composiciones y uso. (divisional solicitud 201800744)
CY1125008T1 (el) Χιμαιρικοι υποδοχεις αντιγονων που στοχευουν συζευγμενους με πρωτεϊνη g yποδοχεις και χρησεις αυτων
CL2021001603A1 (es) Moléculas agonistas de unión al antígeno cd28 que actúan sobre el tumor
MX2019011927A (es) Anticuerpos anti-ilt4 y fragmentos de union a antigeno.
CO2018001405A2 (es) Receptores de antígenos quiméricos basados en anticuerpos de dominio simple
EP3600407C0 (en) ENHANCED FC RECEPTORS (FUSED CD3 CD28 RECEPTORS)
MX389021B (es) Inmunoreceptores especificos de claudina-18.2 y epitopos de celulas t.
MX2021012720A (es) Celulas t de receptor de antigeno quimerico co-estimulador que toman como diana a il13r-alfa-2.
AU2018258045A1 (en) Chimeric antibody/T-cell receptor constructs and uses thereof
MX2020003132A (es) Anticuerpos anti-ctla4 y usos de los mismos.
CO2017006740A2 (es) Anticuerpos anti–cd79b
CL2017003195A1 (es) Anticuerpos madurados por afinidad y humanizados para fcrh5 y métodos para su uso.
AR105767A1 (es) Proteínas de fusión de unión a gitr multivalentes y multiespecíficas
UY36942A (es) Proteínas de unión a antígeno que activan el receptor de leptina
MX385456B (es) Anticuerpos cd123 y conjugados de los mismos.
MX376026B (es) Inmunoreceptores especificos de claudina-6 y epitopos de celulas t.
NZ741067A (en) Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use
IL284091A (en) Antibodies neutralize the type 2 immunoglobulin-like leukocyte receptor
CO2020014343A2 (es) Anticuerpos específicos para cd3 y sus usos
EP3757133A4 (en) ISOLATED ANTIGENIC CHEMICAL RECEPTOR, MODIFIED T LYMPHOCYTE INCLUDING IT AND ASSOCIATED USE
SG11201908659RA (en) Chimeric antigen receptor
MX2019011225A (es) Células t modificadas por el receptor de antígeno quimérico dirigidas a cs1 para el tratamiento de la amiloidosis al.
MX2021002750A (es) Anticuerpos anti-tnfrsf9 y usos de los mismos.